Menu
Back to User profile » Dr Gail Torkildsen
Papers published by Dr Gail Torkildsen:
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC
Clinical Ophthalmology 2019, 13:403-413
Published Date: 19 February 2019
A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease
Taylor M, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, Duggal A
Clinical Ophthalmology 2019, 13:261-275
Published Date: 12 February 2019
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
Meier EJ, Torkildsen GL, Gomes PJ, Jasek MC
Clinical Ophthalmology 2018, 12:2617-2628
Published Date: 13 December 2018
The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
Stonecipher KG, Torkildsen GL, Ousler III GW, Morris S, Villanueva L, Hollander DA
Clinical Ophthalmology 2016, 10:887-895
Published Date: 13 May 2016
Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye
Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW III
Clinical Ophthalmology 2013, 7:1275-1285
Published Date: 26 June 2013
Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial
Patane MA, Cohen A, From S, Torkildsen G, Welch D, Ousler GW 3rd
Clinical Ophthalmology 2011, 5:633-643
Published Date: 15 May 2011
The effects of lubricant eye drops on visual function as measured by the Inter-blink interval Visual Acuity Decay test
Gail Torkildsen
Clinical Ophthalmology 2009, 3:501-506
Published Date: 11 September 2009